Advanced in Chronic B-Cell Leukemia (CBCL)

Zengjun Q. Li

Chinese Academy Of Medical Sciences And Peking Union Medical College, 
Beijing, CN 
Advanced in Chronic B-Cell Leukemia (CBCL)
Chinese Academy Of Medical Sciences And Peking Union Medical College, 
Beijing, CN 
OverviewLocationsClinical Research

Overview

Zengjun Li practices in Beijing, China. Li is rated as an Advanced expert by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). Their top areas of expertise are Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, Bone Marrow Transplant, and Carotid Artery Surgery.

Their clinical research consists of co-authoring 74 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 14 articles and participated in 1 clinical trial in the study of Chronic B-Cell Leukemia (CBCL).

Locations

Chinese Academy Of Medical Sciences And Peking Union Medical College, Beijing, 100021, China
Other Locations
Jinan, China
Tianjin, China
Qingdao, 266003, China
State Key Laboratory Of Experimental Hematology, Chinese Academy Of Medical Sciences And Peking Union Medical College, No. 288 Nanjing Road, 3000241, Xiaobailou, 300024, China
State Key Laboratory Of Experimental Hematology, CAMS & PUMC, 300020, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3
Observational, Non-interventional, Multicenter Study Aimed at Collecting Prospective Data Related to Study Safety and Effectiveness in Real Clinical Practice in Patients With CD30+ Lymphoma (BRAVE Study)
Observational, Non-interventional, Multicenter Study Aimed at Collecting Prospective Data Related to Study Safety and Effectiveness in Real Clinical Practice in Patients With CD30+ Lymphoma (BRAVE Study)
Enrollment Status: Active_not_recruiting
Publish Date: January 27, 2025
Intervention Type: Other
View 1 Less Clinical Trial

74 Total Publications

Zanubrutinib plus R-CHOP for the treatment of newly diagnosed double-expressor lymphoma: A phase 2 clinical study.
Zanubrutinib plus R-CHOP for the treatment of newly diagnosed double-expressor lymphoma: A phase 2 clinical study.
Journal: Cancer
Published: September 11, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Li's expertise for a condition
ConditionClose
      View All 20 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile